CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition

On May2, 2019, Catalyst Biosciences, Inc., issued a press release announcing its financial results for the quarter ended March31, 2019. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form8-K.

The information set forth in this Item 2.02 (including Exhibit 99.1) shall not be deemed filed for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing.

Item 2.02. Financial Statements and Exhibits

(d) Exhibits

Press release dated May2, 2019 and titled Catalyst Biosciences Reports First Quarter 2019 Operating Financial Results and Provides a Corporate Update.


CATALYST BIOSCIENCES, INC. Exhibit
EX-99.1 2 d740978dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Catalyst Biosciences Reports First Quarter 2019 Operating & Financial Results and Provides a Corporate Update Final MarzAA Phase 2 data to be presented at upcoming International Society for Thrombosis & Hemostasis (ISTH) meeting in July 2019 MarzAA Orphan Drug Designation received from the European Commission Initiated DalcA Phase 2b Trial for the Treatment of Hemophilia B SOUTH SAN FRANCISCO,…
To view the full exhibit click here

About CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO)

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.